切换导航
  • 比较产品
我的购物车

若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系

STEMdiff™ 间充质祖细胞试剂盒

用于分化和扩增间充质祖细胞的成分明确的培养试剂盒
率先评论此产品
添加并比较

产品号 #（选择产品）

产品号 #05240_C

用于分化和扩增间充质祖细胞的成分明确的培养试剂盒

产品优势

  • 无血清、无动物成分的配方
  • 可高效且重复性良好地从人胚胎干细胞（ES）和诱导多能干细胞（iPS）系中生成间充质祖细胞（MPCs）
  • 3 周内快速诱导生成 MPCs
  • 所生成的 MPCs 可长期扩增，并具备向脂肪细胞、成骨细胞和软骨细胞分化的能力

产品组分包括

  • STEMdiff™-ACF 间充质诱导培养基，100 mL
  • MesenCult™-ACF Plus 培养基，500 mL
  • MesenCult™-ACF Plus 500X 补充剂，1 mL
  • 无动物成分细胞附着基质，1 mL
main product photo
Need a high-quality cell source? Use the hiPSC SCTi003-A (female) or SCTi004-A (male) control lines, manufactured with mTeSR™ Plus.
专为您的实验方案打造的产品
要查看实验方案所需的所有配套产品，请参阅《实验方案与技术文档》。
  1. Animal Component-Free Cell Dissociation Kit
    Animal Component-Free Cell Dissociation Kit

    Dissociation kit for human stem and progenitor cells

  2. Vitronectin XF™
    Vitronectin XF™

    Defined, xeno-free matrix that supports the growth and differentiation of human pluripotent stem cells under serum-free, feeder-free conditions

  3. Y-27632 (Dihydrochloride)
    Y-27632 (Dihydrochloride)

    RHO/ROCK pathway inhibitor; Inhibits ROCK1 and ROCK2

  4. mTeSR™1
    mTeSR™1

    cGMP, feeder-free maintenance medium for human ES and iPS cells

总览
实验数据
产品说明书及文档
应用领域
相关材料与文献
相关产品

总览

STEMdiff™ 间充质祖细胞试剂盒是一款成分明确的培养试剂盒，包含无动物成分 (ACF) 诱导培养基、扩增培养基和贴壁基质。该试剂盒经过优化，适用于从人胚胎干细胞 (ES) 或诱导多能干细胞 (iPS) 中诱导获得具有间充质祖细胞 (MPC) 样特性的细胞。该试剂盒提供完整的工作流程，包含用于诱导和扩增人ES或iPS衍生 MPC 的成分明确的试剂。CollPlant是细胞贴壁基质中 rhCollagen 成分的制造商。

本产品仅供研究使用。如有任何临床或商业应用需求，请联系 STEMCELL。

本产品仅供研究使用。如有任何临床或商业应用需求，请联系 STEMCELL。

本产品仅供研究使用。如有任何临床或商业应用需求，请联系 STEMCELL。

本产品仅供研究使用。如有任何临床或商业应用需求，请联系 STEMCELL。

亚型
专用培养基
 
细胞类型
间充质细胞，PSC衍生
 
种属
人
 
应用
细胞培养，分化
 
品牌
STEMdiff
 
研究领域
干细胞生物学
 
制剂类别
Animal Component-Free，无血清
 

查看更多 显示更少

实验数据

Human ES- and iPS-derived MPCs Can Be Further Differentiated Into Adipogenic, Chondrogenic and Osteogenic Lineages

Figure 1. Schematic of Differentiation Protocol and Timeline

In Phase 1, human ES or iPS cells are cultured in mTeSR™1 or TeSR™-E8™ medium. On Day 0 (Phase 2) of the protocol, cells are ready for induction into early mesoderm progenitor cells by replacing TeSR™ medium with STEMdiff™ Mesenchymal Induction Medium. By Day 4 (Phase 3), STEMdiff™ Mesenchymal Induction Medium is replaced with MesenCult™-ACF Medium to derive early mesenchymal progenitor cells (MPCs). On Day 6, cells are passaged onto cultureware precoated with MesenCult™-ACF Attachment Substrate in MesenCult™-ACF Medium. By Day 21, human ES- or iPS-derived MPCs exhibit the suggested MPC characteristics.

Cell Expansion and Doubling Rate of MPCs Derived from Human ES (H9) and iPS (STiPS-F016 and -F031) Cells in MesenCult™-ACF Medium

Figure 2. Cell Expansion and Doubling Rate of MPCs Derived from Human ES (H9) and iPS (STiPS-F016 and -F031) Cells in MesenCult™-ACF Medium

(A) The average cell expansion per passage over 17 passages for MPCs derived from human ES and iPS cell lines are approximately 9 and 10 fold. (B) Days to double cell number for human ES- and iPS-derived MPCs range from 1.1 to 1.4 days.

A Representative Flow Cytometric Analysis of STiPS-F016-derived MPCs Expressing Mesenchymal Surface Markers By Day 21

Figure 3. A Representative Flow Cytometric Analysis of STiPS-F016-derived MPCs Expressing Mesenchymal Surface Markers By Day 21

Human iPS-derived MPCs, generated using the STEMdiff™ Mesenchymal Progenitor Kit, express high levels of mesenchymal surface markers (CD73, CD90 and CD105) and the perivascular marker, CD146. MPCs do not express hematopoietic (CD34, CD45) and endothelial (CD144) surface markers. Human ES-derived MPCs express the same phenotype (data not shown).

Human ES- and iPS-derived MPCs Can Be Further Differentiated Into Adipogenic, Chondrogenic and Osteogenic Lineages

Figure 4. Human ES- and iPS-derived MPCs Can Be Further Differentiated Into Adipogenic, Chondrogenic and Osteogenic Lineages

(A) MPCs generated from the 3 week protocol (described in Figure 1) and subsequently cultured in MesenCult™-ACF Medium develop MPC-like morphology (40X magnification). MPCs can be differentiated to (B) adipocytes (Oil Red O staining), 400X magnification; (C) chondrocytes (Alcian Blue staining), 100X magnification; and (D) osteoblasts (Fast Red and Silver Nitrate staining), 100X magnification.

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。

Document Type
Product Name
Catalog #
Lot #
Language
Document Type
Product Information Sheet
Product Name
STEMdiff™ Mesenchymal Progenitor Kit
Catalog #
05240
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Product Name
STEMdiff™ Mesenchymal Progenitor Kit
Catalog #
05240
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Product Name
STEMdiff™ Mesenchymal Progenitor Kit
Catalog #
05240
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Product Name
STEMdiff™ Mesenchymal Progenitor Kit
Catalog #
05240
Lot #
All
Language
English
Document Type
Safety Data Sheet 4
Product Name
STEMdiff™ Mesenchymal Progenitor Kit
Catalog #
05240
Lot #
All
Language
English

应用领域

本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。

Research Area
Workflow Stages

相关材料与文献

技术资料 (8)

qPCR Arrays for Cell Characterization
Brochure
qPCR Arrays for Cell Characterization
Products for Your Mesenchymal Stromal Cell Research
Brochure
Products for Your Mesenchymal Stromal Cell Research
Products for Human Pluripotent Stem Cells
Brochure
Products for Human Pluripotent Stem Cells
hPSC Differentiation: Tools for Pluripotent Stem Cell-Derived Research
Brochure
hPSC Differentiation: Tools for Pluripotent Stem Cell-Derived Research
Directed Differentiation of Pluripotent Stem Cells
Wallchart
Directed Differentiation of Pluripotent Stem Cells
The Identity and Properties of Mesenchymal Stem Cells
Wallchart
The Identity and Properties of Mesenchymal Stem Cells
STEMdiff™ Kits for Robust and Efficient Differentiation of hPSCs to Multiple Cell Types
20:24
Webinar
STEMdiff™ Kits for Robust and Efficient Differentiation of hPSCs to Multiple Cell Types
Defined Culture Conditions for Efficient Derivation Expansion and Cryopreservation of Mesenchymal Progenitor Cells from Human Pluripotent Stem Cells
Scientific Poster
Defined Culture Conditions for Efficient Derivation Expansion and Cryopreservation of Mesenchymal Pr...

文献 (6)

Induced pluripotency and spontaneous reversal of cellular aging in supercentenarian donor cells. J. Lee et al. Biochemical and biophysical research communications 2020 may

Abstract

Supercentenarians (≥110-year-old, SC) are a uniquely informative population not only because they surpass centenarians in age, but because they appear to age more slowly with fewer incidences of chronic age-related disease than centenarians. We reprogramed donor B-lymphoblastoid cell lines (LCL) derived from a 114-year-old (SC), a 43-year-old healthy disease-free control (HDC) and an 8-year-old with a rapid aging disease (Hutchinson-Gilford progeria syndrome (HGPS)) and compared SC-iPSC to HDC-iPSC and HGPS-iPSCs. Reprogramming to pluripotency was confirmed by pluripotency marker expression and differentiation to 3 germ-layers. Each iPSC clone differentiated efficiently to mesenchymal progenitor cells (MPC) as determined by surface marker expression and RNAseq analysis. We identified supercentenarian and HGPS associated gene expression patterns in the differentiated MPC lines that were not evident in the parental iPSC lines. Importantly, telomere length resetting occurred in iPSC from all donors albeit at a lower incidence in supercentenarian iPSCs. These data indicate the potential to use reprogramming to reset both developmental state and cellular age in the oldest of the old." We anticipate that supercentenarian iPSC and their differentiated derivatives will be valuable tools for studying the underlying mechanisms of extreme longevity and disease resistance."
View publication
Intravenous administration of iPS-MSCSPIONs mobilized into CKD parenchyma and effectively preserved residual renal function in CKD rat. J.-J. Sheu et al. Journal of cellular and molecular medicine 2020 mar

Abstract

This study traced intravenously administered induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSC) and assessed the impact of iPSC-MSC on preserving renal function in SD rat after 5/6 nephrectomy. The results of in vitro study showed that FeraTrack™Direct contrast particles (ie intracellular magnetic labelling) in the iPSC-MSC (ie iPS-MSCSPIONs ) were clearly identified by Prussian blue stain. Adult-male SD rats (n = 40) were categorized into group 1 (SC), group 2 [SC + iPS-MSCSPIONs (1.0 × 106 cells)/intravenous administration post-day-14 CKD procedure], group 3 (CKD), group 4 [CKD + iPS-MSCSPIONs (0.5 × 106 cells)] and group 5 [CKD + iPS-MSCSPIONs (1.0 × 106 cells)]. By day-15 after CKD induction, abdominal MRI demonstrated that iPS-MSCSPIONs were only in the CKD parenchyma of groups 4 and 5. By day 60, the creatinine level/ratio of urine protein to urine creatinine/kidney injury score (by haematoxylin and eosin stain)/fibrotic area (Masson's trichrome stain)/IF microscopic finding of kidney injury molecule-1 expression was lowest in groups 1 and 2, highest in group 3, and significantly higher in group 4 than in group 5, whereas IF microscopic findings of podocyte components (ZO-1/synaptopodin) and protein levels of anti-apoptosis ((Bad/Bcl-xL/Bcl-2) exhibited an opposite pattern to creatinine level among the five groups (all P {\textless} .0001). The protein expressions of cell-proliferation signals (PI3K/p-Akt/m-TOR, p-ERK1/2, FOXO1/GSK3$\beta$/p90RSK), apoptotic/DNA-damage (Bax/caspases8-10/cytosolic-mitochondria) and inflammatory (TNF-$\alpha$/TNFR1/TRAF2/NF-$\kappa$B) biomarkers displayed an identical pattern to creatinine level among the five groups (all P {\textless} .0001). The iPS-MSCSPIONs that were identified only in CKD parenchyma effectively protected the kidney against CKD injury.
View publication
Precision installation of a highly efficient suicide gene safety switch in human induced pluripotent stem cells. Z.-D. Shi et al. Stem cells translational medicine 2020 jul

Abstract

Human pluripotent stem cells including induced pluripotent stem cells (iPSCs) and embryonic stem cells hold great promise for cell-based therapies, but safety concerns that complicate consideration for routine clinical use remain. Installing a safety switch" based on the inducible caspase-9 (iCASP9) suicide gene system should offer added control over undesirable cell replication or activity. Previous studies utilized lentiviral vectors to integrate the iCASP9 system into T cells and iPSCs. This method results in random genomic insertion of the suicide switch and inefficient killing of the cells after the switch is "turned on" with a small molecule (eg AP1903). To improve the safety and efficiency of the iCASP9 system for use in iPSC-based therapy we precisely installed the system into a genomic safe harbor the AAVS1 locus in the PPP1R12C gene. We then evaluated the efficiencies of different promoters to drive iCASP9 expression in human iPSCs. We report that the commonly used EF1$\alpha$ promoter is silenced in iPSCs and that the endogenous promoter of the PPP1R12C gene is not strong enough to drive high levels of iCASP9 expression. However the CAG promoter induces strong and stable iCASP9 expression in iPSCs and activation of this system with AP1903 leads to rapid killing and complete elimination of iPSCs and their derivatives including MSCs and chondrocytes in vitro. Furthermore iPSC-derived teratomas shrank dramatically or were completely eliminated after administration of AP1903 in mice. Our data suggest significant improvements on existing iCASP9 suicide switch technologies and may serve as a guide to other groups seeking to improve the safety of stem cell-based therapies."
View publication
View All Publications

更多信息

更多信息
种属 Human
配方类别 Animal Component-Free, Serum-Free
质量保证:

产品仅供研究使用，不用于针对人或动物的诊断或治疗。 欲获悉更多关于STEMCELL的质控信息，请访问 STEMCELL.CN/COMPLIANCE.
Copyright © 2025 by STEMCELL Technologies. All rights reserved.